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Accepted 13 September 2011AbstractObjective: Vulvar cancer is rare in Eastern females, especially in pre- and peripubertal girls. The prognosis of vulvar cancer is poor and treatment
is variable.
Case Report: A 14-year-old girl suffered from a left vulvar tenderness mass and underwent excision of the mass. The diagnosis of the pathology
was vulvar yolk tumor with an embryonal carcinoma. After the vulvectomy, inguinal area lymph node dissection, chemotherapy (bleomycin,
etoposide and cisplatin) treatment and radiotherapy, metastasis to lung was also noted after eight months. Resection of lung tumor was per-
formed. She received chemotherapy with a combination of paclitaxel, ifosphamide and cisplatin (TIP) and received peripheral blood stem cell
transplantation (PBSCT) twice and chemotherapy treatment of gemitabine and oxaliplatin (GEMOX). Up until now, the patient has been free of
disease.
Conclusion: High-dose TIP and GEMOX chemotherapy plus PBSCT for bone marrow rescues could be considered to treat patients with
metastatic malignant vulvar germ cell tumor after failed first-line chemotherapy and radiation.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Vulvar yolk sac tumor is a rare but highly malignant tumor.
To our knowledge, there were only 11 cases reported in
literature until now [1e5]. But among these cases, there was
only one case of vulvar yolk sac tumor combined with an
embryonal carcinoma reported in 1978. There was a variety of
treatment modality in these cases due to the rarity of vulvar
yolk sac tumor. In this report, a girl with vulvar yolk sac
tumor, an embryonal carcinoma and a lung metastasis with
a stable condition after a combination treatment of surgery,* Corresponding author. 2Yuh-Der Road, Taichung 403, Taiwan.
E-mail address: lsyeh@mail.cmuh.org.tw (L.-S. Yeh).
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cell transplantation (PBSCT) was presented.Case report
A 14 year-old female student with progressive enlargement
of left tender vulvar mass in one month was referred to
University Hospital for gynecologic evaluation in September
2007. On physical examination, a 5  4 cm tender mass with
well margin was located at left major labia and no palpable
inguinal lymph node was found. The personal and family
history of the patient was negative. This patient had normal
development of breast, axillary and pubic hair. Excision of the
mass was performed under intravenous general anesthesia incs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 2. Yolk sac tumor (right upper) revealing solid, microacinar, trabecular
growth pattern and embryonal carcinoma (left lower) disclosing solid or
glandular architecture with vesicular nuclei and prominent nucleoli, presence
of foci of peritumoral intravascular microthrombi of both components, mild to
moderate lymphoplasmacytic tumor-host reaction. (100, H&E stain).
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revealed a mixed germ cell composed yolk sac tumor (85%)
and an embryonal carcinoma (15%) (Figs. 1e4). However, the
tumor was present on the cut surface of the excision. After
excision, a laboratory test showed her AFP level was 25.8 ng/
mL, b-HCG, LDH and CA-125 were within normal limits and
she had a normal 46XX karyotype. Positron emission
tomography (PET) scan showed increased [18F]-2-fluoro-
deoxy-D-glucose (FDG) uptake in the vulvar region. Magnetic
resonance imaging (MRI) revealed several enlarged lymph
nodes in the bilateral inguinal region. The patient received
three courses of BEP chemotherapy (bleomycin 15 mg/m2 iv
weekly, etoposide 100 mg/m2 and cisplatin 20 mg/m2 Day 1 to
3 for both) given at 21-day intervals. AFP returned to normal
limits in November 2007. After completion of three courses of
chemotherapy, simple vulvectomy and bilateral inguinal
lymph node dissection were performed. In the pathology
report there was no residual tumor and no lymph node
involvement. The patient was followed up monthly at OPD.
Until July 2008, AFP was elevated to 12.36 ng/mL. MRI
showed a 1.5 cm lymph node in left inguinal region and PET
scan showed focal intensely increased FDG uptake in the left
vulvar, left posteromost upper intrapelvic region and the
inguinal region. After counseling with a radiation oncologist,
radiation therapy with total dose 60 Gy/30 Fr were completed
in August 2008. AFP returned to 0.98 ng/mL after radiation.
However, one year after radiation APF elevated to 11.14 ng/
mL. A chest X-ray showed a nodule over the left lower lobe
(LLL) of the lung. MRI and computed tomography (CT) scan
showed a 1.6 cm nodule in the lateral basal segment of the
LLL of the lung. Tl-201 cancer work-up found an increased
tracer uptake in the lung and perineal region. The patient
received thoracoscopic wedge resection of the LLL of the lung
and mediastinal lymph node dissection in September 2009.
The pathology report revealed metastatic yolk sac tumor with
an embryonal carcinoma and one lymph node was involved. InFig. 1. Presence of a spider-weblike network formed by vacuolated cytoplasm
of tumor cells, similar to a honeycomb (100, H&E stain).October 2009, the AFP level increased to 17.06 ng/mL. The
patient was administered four courses of high-dose TIP
chemotherapy (paclitaxel 250 mg/m2 over 24 hours on Day 1,
followed by ifosfamide 1500 mg/m2 and cisplatin 25 mg/m2
per day on Days 2 to 6) at 21-day intervals. Chemotherapy was
completed in December 2009 and AFP subsequently
decreased to 1.33 ng/mL. The patient received PBSCT in
February and March 2010 and three courses of GEMOX
chemotherapy (gemcitabine 1500 mg/m2, intravenously on
Days 1 and 8 and oxaliplatin 130 mg/m2 on Day 8 every 21
days). After treatment, the patient had follow-up of a FDG
PET/CT whole body scan which did not show any focally
hypermetabolic lesions. Up until now, this patient has been
well and the tumor marker is normal.Fig. 3. Schiller-Duvall body characterized by the presence of a central vessel,
surrounded by fibrous tissue and epithelial tumor cells, in a space lined by flat
tumor cells. (200, H&E stain).
Fig. 4. Embryonal carcimoa showed glandular pattern with sheets, glands and
nests of malignant large ovoid or polygonal cells with pleomorphic nuclei.
(200, H&E stain).
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Vulvar tumor is rarely seen in girls but it is important to
make a differential diagnosis of benign tumor or malignancy.
Most benign vulvar masses have well defined margins without
tenderness and potentially malignant masses are not well
defined and the patient could have symptoms of tenderness
[6]. In this case, the patient presented signs of an infection and
had antibiotic treatment at clinics which failed so she was
referred to the University Hospital for management.
Malignant vulvar germ cell tumor is rare and the majority
are pure yolk sac tumors. The commonly used treatment for
malignant vulvar yolk sac tumor is conservative surgery (local
or wide excision combined with/without inguinal lymph node
sampling or dissection) followed by adjuvant chemotherapy.
The chemotherapy traditionally used in treating germ cell
tumor was BEP, PVB (cispltain, vincristine and bleomycin) or
VAC (vincristine, dactinomycin and cyclophosphamide).
However, the regimen is commonly used in the treatment of
ovarian cancer and some patients had resistance to a cisplatin-
based regimen in treating vulvar cancer [7]. In this case, the
patient accepted BEP treatment first but the tumor marker was
elevated and the recurrence noted at the inguinal area lymph
node within one year after chemotherapy. In previous reports,
most recurrent or metastatic sites were the inguinal lymph
node or pleura/lung and recurrence mainly occurred within
two years. Adjuvant radiation therapy was the choice to treat
recurrence but three cases died within two years, so treatment
for this patient with recurrence was a critical issue. Konda-
gunta et al study showed 65% of patients with relapsed
testicular germ cell tumor had two-year progression-free
survival after the second-line high-dose TIP chemotherapy [8].
Mead et al study also revealed the good response with high-dose TIP treatment for patients with metastatic malignant
germ cell tumor post BEP chemotherapy [9]. However,
salvage high-dose chemotherapy led to 64e70% patients with
grade 3 to 4 leucopenia and 7% had grade 4 to 5 renal toxicity.
Autologous bone marrow cells transplantation has been re-
ported as benefiting patients by rescuing the hematopoietic
system after high-dose chemotherapy. In this case, the patient
accepted PBSCT twice for rescue. The patient then received
GEMOX chemotherapy treatment which was used in patients
with non-small lung cancer and both refractory or sensitive
ovarian cancer and had moderate and tolerable side effects and
toxicity [10,11]. During the three courses of GEMOX
chemotherapy, this patient did not suffer pancytopenia or
severe nausea and vomiting.
In conclusion, a vulvar mass of a young girl is rare and it is
important to make correct diagnosis. High-dose TIP and
GEMOX chemotherapy plus PBSCT for rescues could be
considered to treat patients with metastatic malignant or
recurrent vulvar germ cell tumor after failed first-line
chemotherapy and radiation.References
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